Basket | Login | Register

 
 
 
 

Clinical trials by country

Clinical Trials Watch

Austria

  1. CREAD
  2. ENGAGE
  3. MISSIONAD1 (planned)

Belgium

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ
  4. EARLY
  5. EMERGE
  6. GENERATION S1

Bulgaria

  1. COGNITE
  2. CREAD
  3. MISSIONAD1 (planned)

Croatia

  1. CREAD
  2. MISSIONAD2 (planned)

Czech Republic

  1. COGNITE
  2. CREAD
  3. DAYBREAK-ALZ
  4. MISSIONAD1 
  5. MISSIONAD2 (planned)

Denmark

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ
  4. EARLY
  5. ENGAGE
  6. MISSIONAD2 (planned)

Estonia

  1. CREAD2

Finland

  1. CREAD
  2. EARLY
  3. EMERGE
  4. GENERATION S1
  5. MISSIONAD2 (planned)

France

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ
  4. EMERGE
  5. ENGAGE
  6. MISSIONAD1
  7. MISSIONAD2

Germany

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ
  4. EARLY
  5. EMERGE
  6. ENGAGE
  7. MISSIONAD1 (planned)
  8. MISSIONAD2 (planned)

Greece

  1. MISSIONAD1 (planned)

Hungary

  1. COGNITE
  2. CREAD
  3. MISSIONAD2

Italy

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ
  4. EARLY
  5. EMERGE
  6. ENGAGE
  7. MISSIONAD2 (planned)

Lithuania

  1. CREAD

Netherlands

  1. DAYBREAK-ALZ
  2. EARLY
  3. EMERGE
  4. GENERATION S1

Norway

  1. CREAD2

Poland

  1. COGNITE
  2. CREAD
  3. CREAD2
  4. DAYBREAK-ALZ
  5. EMERGE
  6. MISSIONAD1
  7. MISSIONAD2

Portugal

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ
  4. ENGAGE
  5. MISSIONAD2 (planned)

Romania

  1. MISSIONAD1 (planned)

Russia

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ

Serbia

  1. CREAD2
  2. MISSIONAD1 (planned)

Slovakia

  1. MISSIONAD2

Slovenia

  1. CREAD

Spain

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ
  4. EARLY
  5. EMERGE
  6. ENGAGE
  7. GENERATION S1
  8. MISSIONAD1
  9. MISSIONAD2

Sweden

  1. CREAD
  2. CREAD2
  3. EARLY
  4. EMERGE
  5. MISSIONAD1 (planned)

Switzerland

  1. CREAD
  2. EARLY (planned)
  3. EMERGE
  4. GENERATION S1

Turkey

  1. CREAD
  2. CREAD2

Ukraine

  1. CREAD

UK

  1. CREAD
  2. CREAD2
  3. DAYBREAK-ALZ
  4. EARLY
  5. ENGAGE
  6. MISSIONAD1
  7. SYMBAD

 

 
 

Last Updated: Tuesday 06 February 2018

 

 
 

Options